Ahn, Ki Jung
(Department of Radiation Oncology, Inje University College of Medicine)
,
Lee, Hyung Sik
(Department of Radiation Oncology, Dong-A University College of Medicine)
,
Bai, Se Kyung
(Department of Biochemistry, Kangwon National University)
,
Song, Chang Won
(Radiobiology Laboratory, Department of Therapeutic Radiology, University of Minnesota Medical School)
Beta-lapachone (${\beta}$-Lap; 3,4-dihydro-2, 2-dimethyl-2H-naphthol[1, 2-b]pyran-5,6-dione) is a novel anti-cancer drug under phase I/II clinical trials. ${\beta}$-Lap has been demonstrated to cause apoptotic and necrotic death in a variety of human cancer cells in vitro and i...
Beta-lapachone (${\beta}$-Lap; 3,4-dihydro-2, 2-dimethyl-2H-naphthol[1, 2-b]pyran-5,6-dione) is a novel anti-cancer drug under phase I/II clinical trials. ${\beta}$-Lap has been demonstrated to cause apoptotic and necrotic death in a variety of human cancer cells in vitro and in vivo. The mechanisms underlying the ${\beta}$-Lap toxicity against cancer cells has been controversial. The most recent view is that ${\beta}$-Lap, which is a quinone compound, undergoes two-electron reduction to hydroquinone form utilizing NAD(P)H or NADH as electron source. This two-electron reduction of ${\beta}$-Lap is mediated by NAD(P)H:quinone oxidoreductase (NQO1), which is known to mediate the reduction of many quinone compounds. The hydroquinone forms of ${\beta}$-Lap then spontaneously oxidizes back to the original oxidized ${\beta}$-Lap, creating futile cycling between the oxidized and reduced forms of ${\beta}$-Lap. It is proposed that the futile recycling between oxidized and reduced forms of ${\beta}$-Lap leads to two distinct cell death pathways. First one is that the two-electron reduced ${\beta}$-Lap is converted first to one-electron reduced ${\beta}$-Lap, i.e., semiquinone ${\beta}$-Lap $(SQ)^{{\cdot}-}$ causing production of reactive oxygen species (ROS), which then causes apoptotic cell death. The second mechanism is that severe depletion of NAD(P)H and NADH as a result of futile cycling between the quinone and hydroquinone forms of ${\beta}$-Lap causes severe disturbance in cellular metabolism leading to apoptosis and necrosis. The relative importance of the aforementioned two mechanisms, i.e., generation of ROS or depletion of NAD(P)H/NADH, may vary depending on cell type and environment. Importantly, the NQO1 level in cancer cells has been found to be higher than that in normal cells indicating that ${\beta}$-Lap may be preferentially toxic to cancer cells relative to non-cancer cells. The cellular level of NQO1 has been found to be significantly increased by divergent physical and chemical stresses including ionizing radiation. Recent reports clearly demonstrated that ${\beta}$-Lap and ionizing radiation kill cancer cells in a synergistic manner. Indications are that irradiation of cancer cells causes long-lasting elevation of NQO1, thereby sensitizing the cells to ${\beta}$-Lap. In addition, ${\beta}$-Lap has been shown to inhibit the repair of sublethal radiation damage. Treating experimental tumors growing in the legs of mice with irradiation and intraperitoneal injection of ${\beta}$-Lap suppressed the growth of the tumors in a manner more than additive. Collectively, ${\beta}$-Lap is a potentially useful anti-cancer drug, particularly in combination with radiotherapy.
Beta-lapachone (${\beta}$-Lap; 3,4-dihydro-2, 2-dimethyl-2H-naphthol[1, 2-b]pyran-5,6-dione) is a novel anti-cancer drug under phase I/II clinical trials. ${\beta}$-Lap has been demonstrated to cause apoptotic and necrotic death in a variety of human cancer cells in vitro and in vivo. The mechanisms underlying the ${\beta}$-Lap toxicity against cancer cells has been controversial. The most recent view is that ${\beta}$-Lap, which is a quinone compound, undergoes two-electron reduction to hydroquinone form utilizing NAD(P)H or NADH as electron source. This two-electron reduction of ${\beta}$-Lap is mediated by NAD(P)H:quinone oxidoreductase (NQO1), which is known to mediate the reduction of many quinone compounds. The hydroquinone forms of ${\beta}$-Lap then spontaneously oxidizes back to the original oxidized ${\beta}$-Lap, creating futile cycling between the oxidized and reduced forms of ${\beta}$-Lap. It is proposed that the futile recycling between oxidized and reduced forms of ${\beta}$-Lap leads to two distinct cell death pathways. First one is that the two-electron reduced ${\beta}$-Lap is converted first to one-electron reduced ${\beta}$-Lap, i.e., semiquinone ${\beta}$-Lap $(SQ)^{{\cdot}-}$ causing production of reactive oxygen species (ROS), which then causes apoptotic cell death. The second mechanism is that severe depletion of NAD(P)H and NADH as a result of futile cycling between the quinone and hydroquinone forms of ${\beta}$-Lap causes severe disturbance in cellular metabolism leading to apoptosis and necrosis. The relative importance of the aforementioned two mechanisms, i.e., generation of ROS or depletion of NAD(P)H/NADH, may vary depending on cell type and environment. Importantly, the NQO1 level in cancer cells has been found to be higher than that in normal cells indicating that ${\beta}$-Lap may be preferentially toxic to cancer cells relative to non-cancer cells. The cellular level of NQO1 has been found to be significantly increased by divergent physical and chemical stresses including ionizing radiation. Recent reports clearly demonstrated that ${\beta}$-Lap and ionizing radiation kill cancer cells in a synergistic manner. Indications are that irradiation of cancer cells causes long-lasting elevation of NQO1, thereby sensitizing the cells to ${\beta}$-Lap. In addition, ${\beta}$-Lap has been shown to inhibit the repair of sublethal radiation damage. Treating experimental tumors growing in the legs of mice with irradiation and intraperitoneal injection of ${\beta}$-Lap suppressed the growth of the tumors in a manner more than additive. Collectively, ${\beta}$-Lap is a potentially useful anti-cancer drug, particularly in combination with radiotherapy.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
문제 정의
Recent studies clearly demonstrated that -Lap is not only cytotoxic by itself but it also potentiates the response of cancer cells to ionizing radiation (IR) [3-6], chemotherapy [7], and hyperthermia [8-11]. The purpose of this article is to review recent reports on the molecular mechanisms underlying the anti-cancer effect of j3-Lap alone or in combination with ionizing radiation.
참고문헌 (50)
1 Pardee AB Li YZ Li CJ Cancer therapy with beta-lapachone Curr Cancer Drug Targets 2002 2 227 242 12188909
2 Planchon SM Wuerzberger S Frydman B Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response Cancer Res 1995 55 3706 3711 7641180
3 Park HJ Ahn KJ Ahn SD Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation Int J Radiat Oncol Biol Phys 2005 61 212 219 15629614
4 Kim EJ Ji IM Ahn KJ Synergistic effect of ionizing radiation and beta-Lapachone against RKO human colon adenocarcinoma cells Cancer Res Treat 2005 37 183 190 19956501
5 Suzuki M Amano M Choi J Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro Radiat Res 2006 165 525 531 16669706
6 Choi EK Terai K Ji IM Upregulation of NAD(P)H:quinine oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells Neoplasia 2007 9 634 642 17786182
7 Terai K Dong GZ Oh ET Cisplatin enhances the anticancer effect of beta-lapachone by upregulating NQO1 Anticancer Drugs 2009 20 901 909 19738461
8 Park HJ Choi EK Choi J Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone Clin Cancer Res 2005 11 8866 8871 16361576
9 Song CW Chae JJ Choi EK Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock Int J Hyperthermia 2008 24 161 169 18283592
10 Dong GZ Youn H Park MT Heat shock increases expression of NAD(P)H:quinone oxidoreductase (NQO1), mediator of beta-lapachone cytotoxicity, by increasing NQO1 gene activity and via Hsp70-mediated stabilisation of NQO1 protein Int J Hyperthermia 2009 25 477 487 19657853
11 Hori T Kondo T Lee H Song CW Park HJ Hyperthermia enhances the effect of β-Lapachone to cause γH2AX formations and cell death in human osteosarcoma cells Int J Hyperthermia 2011 27 53 62 21070139
12 Planchon SM Pink JJ Tagliarino C Bornmann WG Varnes ME Boothman DA beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3 Exp Cell Res 2001 267 95 106 11412042
13 Pink JJ Planchon SM Tagliarino C Varnes ME Siegel D Boothman DA NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity J Biol Chem 2000 275 5416 5424 10681517
14 Pink JJ Wuerzberger-Davis S Tagliarino C Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during beta-lapachone-mediated apoptosis Exp Cell Res 2000 255 144 155 10694431
15 Tagliarino C Pink JJ Dubyak GR Nieminen AL Boothman DA Calcium is a key signaling molecule in beta-lapachone-mediated cell death J Biol Chem 2001 276 19150 19159 11279125
16 Wuerzberger SM Pink JJ Planchon SM Byers KL Bornmann WG Boothman DA Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone Cancer Res 1998 58 1876 1885 9581828
17 Huang L Pardee AB beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells Mol Med 1999 5 711 720 10656873
18 Li Y Sun X LaMont JT Pardee AB Li CJ Selective killing of cancer cells by beta-lapachone: direct checkpoint activation as a strategy against cancer Proc Natl Acad Sci U S A 2003 100 2674 2678 12598645
19 Boothman DA Trask DK Pardee AB Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I Cancer Res 1989 49 605 612 2535961
20 Hueber A Esser P Heimann K Kociok N Winter S Weller M The topoisomerase I inhibitors, camptothecin and beta-lapachone, induce apoptosis of human retinal pigment epithelial cells Exp Eye Res 1998 67 525 530 9878214
21 Li CJ Averboukh L Pardee AB beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin J Biol Chem 1993 268 22463 22468 8226754
22 Weller M Winter S Schmidt C Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone Int J Cancer 1997 73 707 714 9398050
23 Frydman B Marton LJ Sun JS Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones Cancer Res 1997 57 620 627 9044837
24 Krishnan P Bastow KF Novel mechanism of cellular DNA topoisomerase II inhibition by the pyranonaphthoquinone derivatives alpha-lapachone and beta-lapachone Cancer Chemother Pharmacol 2001 47 187 198 11320661
25 Li CJ Li YZ Pinto AV Pardee AB Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints Proc Natl Acad Sci U S A 1999 96 13369 13374 10557327
26 Begleiter A Fourie J Induction of NQO1 in cancer cells Methods Enzymol 2004 382 320 351 15047110
27 Joseph P Xie T Xu Y Jaiswal AK NAD(P)H:quinone oxidoreductase1 (DT-diaphorase): expression, regulation, and role in cancer Oncol Res 1994 6 525 532 7620221
28 Joseph P Jaiswal AK NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase Proc Natl Acad Sci U S A 1994 91 8413 8417 8078896
30 Cullen JJ Hinkhouse MM Grady M Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism Cancer Res 2003 63 5513 5520 14500388
37 Keyes SR Fracasso PM Heimbrook DC Rockwell S Sligar SG Sartorelli AC Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1 Cancer Res 1984 44 5638 5643 6437671
38 Pan SS Andrews PA Glover CJ Bachur NR Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase J Biol Chem 1984 259 959 966 6319393
39 Hodnick WF Sartorelli AC Reductive activation of mitomycin C by NADH:cytochrome b5 reductase Cancer Res 1993 53 4907 4912 8402680
40 Siegel D Franklin WA Ross D Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors Clin Cancer Res 1998 4 2065 2070 9748120
41 Belinsky M Jaiswal AK NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues Cancer Metastasis Rev 1993 12 103 117 8375015
42 Cresteil T Jaiswal AK High levels of expression of the NAD(P)H: quinine oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin Biochem Pharmacol 1991 42 1021 1027 1651729
43 Long DJ 2nd Gaikwad A Multani A Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia Cancer Res 2002 62 3030 3036 12036909
44 Dhakshinamoorthy S Jaiswal AK Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene Oncogene 2001 20 3906 3917 11439354
45 Winski SL Swann E Hargreaves RH Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones Biochem Pharmacol 2001 61 1509 1516 11377380
48 Boveris A Docampo R Turrens JF Stoppani AO Effect of beta-lapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi Biochem J 1978 175 431 439 217340
49 Chau YP Shiah SG Don MJ Kuo ML Involvement of hydrogen peroxide in topoisomerase inhibitor beta-lapachone-induced apoptosis and differentiation in human leukemia cells Free Radic Biol Med 1998 24 660 670 9559879
50 Molina Portela MP Stoppani AO Redox cycling of beta-lapachone and related o-naphthoquinones in the presence of dihydrolipoamide and oxygen Biochem Pharmacol 1996 51 275 283 8573194
※ AI-Helper는 부적절한 답변을 할 수 있습니다.